Engineering Fluor to Undertake Procurement, Construction Management for Biologics Manufacturing Unit

Source: Press release Fluor Corporation

Related Vendors

A large-scale biologics drug substance manufacturing facility is being built in Scandinavia and Fluor Corporation has been chosen to carry out procurement and construction management services for the project. The facility is expected to be operational by 2025.

The facility will produce new capacity for advanced biologics that are used in a variety of treatments including vaccines, oncology and quality-of-life medicines.
The facility will produce new capacity for advanced biologics that are used in a variety of treatments including vaccines, oncology and quality-of-life medicines.
(Source: Pixabay)

Texas/USA – Fluor Corporation has been selected by a leading biologics company to perform procurement and construction management for a large-scale biologics drug substance manufacturing facility located in Scandinavia. Fluor will book the multi-hundred-million-dollar reimbursable contract value in the third quarter of 2022.

The facility will produce new capacity for advanced biologics that are used in a variety of treatments including vaccines, oncology and quality-of-life medicines. Fluor has performed the planning and enabling work for this project, and construction is now underway with the facility scheduled to be operational by 2025.

Fluor’s Advanced Technologies & Life Sciences business is leading the project including support from its Nordic Technology Hub in Copenhagen, Denmark.

(ID:48626588)

Subscribe to the newsletter now

Don't Miss out on Our Best Content

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy.

Unfold for details of your consent